Baseline characteristics of all study patients
belly pain, ALBI, fever
HEPATITIS B, VIRUS, TUMOR PROGRESSION
Nineteen patients (95.0%) started anti‐PD‐1 within 7–10 days after RFA. One patient started anti‐PD‐1 on the 14th day due to belly pain and fever. Nineteen patients (95.0%) completed 4 doses of anti‐PD‐1 and one patient (5.0%) discontinued treatment due to tumor progression.The baseline characteristics of the 40 patients were summarized in Table Baseline characteristics of all study patients.Abbreviations: AFP, alpha‐fetoprotein; ALBI, albumin‐bilirubin; anti‐PD‐1, toripalimab; HBV, hepatitis B virus; RFA, radiofrequency ablation.